From world-class research, to access to a major physician network serving over 2 million patients, HPCGG has the resources needed to start translating genomic results into better health care.

HPCGG is a joint enterprise between Harvard Medical School and Partners HealthCare System, dedicated to accelerating the realization of personalized medicine by discovering and integrating genetic knowledge into the healthcare system.

Raju Kucherlapati, director at HPCGG commented, "If we can improve the accuracy of warfarin dosing by our clinicians, even by modest percentages, we will increase the likelihood that patients will respond to therapy and ultimately we will reduce serious medical complications of therapy.

Upon completion of the study, both HPCGG and Metabolon expect to report results from the collaboration in a peer-reviewed publication.

HPCGG combines world-class scientific talent with access to a population of more than 2 million patients and their physicians, providing a continuum of resources and expertise to rapidly translate scientific discoveries into diagnoses and treatments that benefit patients.

The GIGPAD system was developed by team of information technology, scientific, clinical, and administrative specialists spanning the HPCGG, Partners Healthcare Information Systems and business partner Hewlett Packard.

HPCGG provides Harvard Medical School and Partners with state-of-the-art facilities, technology, training, tools and resources required to promote genetics and genomics in research and clinical medicine.

All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.